Koji Yoshinaga - Concepedia

Author

Koji Yoshinaga

Zeria Pharmaceutical (Japan)

Also Known As

K. YOSHINAGA, K. Yoshinaga, Koji YOSHINAGA, Koji Yoshinaga

Publications

342

Citations

H-Index

Concepts

All Affiliations

Zeria Pharmaceutical (Japan)Central Research Laboratories (United Kingdom)University of Nottingham

About

Koji Yoshinaga is an author at Zeria Pharmaceutical (Japan) specializing in medicine, pharmacology, and tumor microenvironment.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	179
2	Cell Biology	4	4	84
3	Health Sciences	1	1	28
4	Natural Sciences	1	1	33
5	Biochemistry	1	1	33

Koji Yoshinaga

Publications

299

Citations

H-Index

Page 1

	Year	Citations
Effect of Z-360, a novel orally active CCK-2/gastrin receptor antagonist on tumor growth in human pancreatic adenocarcinoma cell lines in vivo and mode of action determinations in vitro Daisuke Kawasaki, Yutaka Emori, Runa Eta, Cancer Chemotherapy and Pharmacology Tumor BiologyAction DeterminationsOncologyPancreatic CancerGastrointestinal Oncology	2007	37
Effect of polaprezinc on taste disorders in zinc‐deficient rats Hiroki Hamano, Koji Yoshinaga, Runa Eta, BioFactors	2006	36
Synthesis of Prolyl Endopeptidase Inhibitors and Evaluation of Their Structure-Activity Relationships: In Vitro Inhibition of Prolyl Endopeptidase from Canine Brain. S Niwa, Koji Yoshinaga, Naoyoshi Miura Chemical and Pharmaceutical Bulletin Pharmaceutical ScienceChemical ModificationPharmacotherapyChemical BiologyPharmaceutical Chemistry	1993	33
Antimetastatic Effect of an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Z-100, through the Production of Interleukin-12 Hideki Oka, Yumiko Shiraishi, Hidetaka Sasaki, Biological and Pharmaceutical Bulletin ImmunologyImmunoeditingImmunologic MechanismImmunotherapyAntimetastatic Effect	2003	28
Z-360, a Novel Therapeutic Agent for Pancreatic Cancer, Prevents Up-Regulation of Ephrin B1 Gene Expression and Phosphorylation of NR2B via Suppression of Interleukin-1β Production in a Cancer-Induced Pain Model in Mice Yuki Orikawa, Hiroki Kato, Koichi Seto, Molecular Pain	2010	27
Anti‐Tumor Mechanism of Z‐100, an Immunomodulatory Arabinomannan Extracted from <i>Mycobacterium tuberculosis</i> Strain Aoyama B, on Pulmonary Metastases of B16F10 Melanoma: Restoration of Helper T Cell Responses via Suppression of Glucocorticoid‐Genesis Hideki Oka, Yutaka Emori, Hidetaka Sasaki, Microbiology and Immunology Inflammatory Lung DiseaseB16f10 MelanomaImmunologyImmune RegulationImmunologic Mechanism	2002	24
Z-100, an Immunomodulatory Arabinomannan Extracted from Mycobacterium tuberculosis Strain Aoyama B, Augments Anti-tumor Activities of X-Ray Irradiation against B16 Melanoma in Association with the Improvement of Type 1T Cell Responses Hideki Oka, Hidetaka Sasaki, Yumiko Shiraishi, Biological and Pharmaceutical Bulletin	2004	23
Pre-clinical evaluation of a new orally-active CCK-2R antagonist, Z-360, in gastrointestinal cancer models Anna M. Grabowska, Teresa Morris, Andrew J. McKenzie, Regulatory Peptides OncologyChemoprevention StrategyGastrointestinal OncologyPre-clinical EvaluationMedicine	2007	22
Effects of zinc deficiency and supplementation on gene expression of bitter taste receptors (TAS2Rs) on the tongue in rats Hiroki Sekine, Kyoichi Takao, Koji Yoshinaga, The Laryngoscope	2012	19
Pharmacological Evaluation of Analgesic Effects of the Cholecystokinin2 Receptor Antagonist Z-360 in Mouse Models of Formalin- and Cancer-Induced Pain Koji Yoshinaga, Takayuki Horii, Hiroki Hamano, Biological and Pharmaceutical Bulletin	2010	15

Page 1